Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 15 (May 20), 2006: pp. 2283-2289
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.5716

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beck, K. E.
Right arrow Articles by Yang, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beck, K. E.
Right arrow Articles by Yang, J. C.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Kimberly E. Beck, Joseph A. Blansfield, Khoi Q. Tran, Andrew L. Feldman, Marybeth S. Hughes, Richard E. Royal, Udai S. Kammula, Suzanne L. Topalian, Richard M. Sherry, David Kleiner, Martha Quezado, Israel Lowy, Michael Yellin, Steven A. Rosenberg, James C. Yang

From the Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD; and Medarex Inc, Princeton NJ

Address reprint requests to James C. Yang, MD, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W, 10 Center Dr, Bethesda, MD 20892-1201; e-mail: James_Yang{at}nih.gov

PURPOSE: Cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented.

PATIENTS AND METHODS: We treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab.

RESULTS: The overall objective tumor response rate was 14%. We observed several immune mediated toxicities including dermatitis, enterocolitis, hypophysitis, uveitis, hepatitis, and nephritis. Enterocolitis, defined by grade 3/4 clinical presentation and/or biopsy documentation, was the most common major toxicity (21% of patients). It presented with diarrhea, and biopsies showed both neutrophilic and lymphocytic inflammation. Most patients who developed enterocolitis responded to high-dose systemic corticosteroids. There was no evidence that steroid administration affected tumor responses. Five patients developed perforation or required colectomy. Four other patients with steroid-refractory enterocolitis appeared to respond promptly to tumor necrosis factor alpha blockade with infliximab. Objective tumor response rates in patients with enterocolitis were 36% for MM and 35% for RCC, compared with 11% and 2% in patients without enterocolitis, respectively (P = .0065 for MM and P = .0016 for RCC).

CONCLUSION: CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.

Supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
    Howard L. Kaufman and Jedd D. Wolchok
    JCO 2006 24: 2230-2232 [Full Text]

Related Correspondence

  • Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?
    Gianluigi Ferretti, Alessandra Felici, Maria Simona Pino, and Francesco Cognetti
    JCO 2006 24: 5469-5470 [Full Text]


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. MacRae, M. Nelson, C. Canning, I. Lowy, et al.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
PNAS, February 26, 2008; 105(8): 3005 - 3010.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Tsatsanis, K. Vaporidi, V. Zacharioudaki, A. Androulidaki, Y. Sykulev, A. N. Margioris, and P. N. Tsichlis
Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells
PNAS, February 26, 2008; 105(8): 2987 - 2992.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, T. E. Allen, C. L. Levy, et al.
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Clin. Cancer Res., November 15, 2007; 13(22): 6681 - 6688.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Zang and J. P. Allison
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clin. Cancer Res., September 15, 2007; 13(18): 5271 - 5279.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. S. Ahuja, C. A. Estrada, and M. L. Lindsey
Crosstalk Between Cytotoxic T-Lymphocyte Associated Antigen-4 and Interleukin-12 in Cytotoxic T-Lymphocyte Mediated Myocarditis: Adding Another Link to the Chain
Circ. Res., August 3, 2007; 101(3): 218 - 220.
[Full Text] [PDF]


Home page
The OncologistHome page
J. Weber
Review: Anti CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Oncologist, July 1, 2007; 12(7): 864 - 872.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Ribas, D. C. Hanson, D. A. Noe, R. Millham, D. J. Guyot, S. H. Bernstein, P. C. Canniff, A. Sharma, and J. Gomez-Navarro
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
Oncologist, July 1, 2007; 12(7): 873 - 883.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, and J. P. Allison
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1810 - 1815.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. O'Mahony, J. C. Morris, C. Quinn, W. Gao, W. H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T. A. Fleisher, et al.
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
Clin. Cancer Res., February 1, 2007; 13(3): 958 - 964.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Yang
In Reply
J. Clin. Oncol., December 1, 2006; 24(34): 5470 - 5471.
[Full Text] [PDF]


Home page
JCOHome page
G. Ferretti, A. Felici, M. S. Pino, and F. Cognetti
Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?
J. Clin. Oncol., December 1, 2006; 24(34): 5469 - 5470.
[Full Text] [PDF]


Home page
JCOHome page
H. L. Kaufman and J. D. Wolchok
Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
J. Clin. Oncol., May 20, 2006; 24(15): 2230 - 2232.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online